This is an observational ambispective cohort study to validate the Baveno VI guideline and develop a new diagnostic model to screen high-risk varices (HRV) of liver cirrhosis using iLivTouch.

Start Date30 Nov 2023

Sponsor / Collaborator

Lanzhou University

[+10]

100 Clinical Results associated with Guilin People's Hospital

0 Patents (Medical) associated with Guilin People's Hospital

252

Literatures (Medical) associated with Guilin People's Hospital

28 Mar 2025·Science Advances

Systematic high-throughput evaluation reveals FrCas9’s superior specificity and efficiency for therapeutic genome editing

Article

Author: Tian, Xun ; Zhong, Chaoyue ; Song, Yuping ; Zhu, Wei ; Zhou, Ping ; Zhao, Tingting ; Yang, Meiying ; Hu, Zheng ; Han, Zhiqiang ; Tian, Rui

CRISPR-Cas9 systems have revolutionized genome editing, but the off-target effects of Cas9 limit its use in clinical applications. Here, we systematically evaluate FrCas9, a variant from Faecalibaculum rodentium , for cell and gene therapy (CGT) applications and compare its performance to SpCas9 and OpenCRISPR-1. OpenCRISPR-1 is a CRISPR system synthesized de novo using large language models (LLMs) but has not yet undergone systematic characterization. Using AID-seq, Amplicon sequencing, and GUIDE-seq, we assessed the on-target activity and off-target profiles of these systems across multiple genomic loci. FrCas9 demonstrated higher on-target efficiency and substantially fewer off-target effects than SpCas9 and OpenCRISPR-1. Furthermore, TREX2 fusion with FrCas9 reduced large deletions and translocations, enhancing genomic stability. Through screening of 1903 sgRNAs targeting 21 CGT-relevant genes using sequential AID-seq, Amplicon sequencing, and GUIDE-seq analysis, we identified optimal sgRNAs for each gene. Our high-throughput screening platform highlights FrCas9, particularly in its TREX2-fused form, as a highly specific and efficient tool for precise therapeutic genome editing.

21 Mar 2025·Medicine

Exploring resistance to initial chemotherapy in small cell lung cancer: The role of bone metastasis and other clinicopathologic characteristics

Article

Author: He, Yulong ; Jiang, Qinling ; Tang, Xiaorong ; Lang, Wenwang ; Yang, Fang ; Deng, Lin

Clinically, approximately 10% to 20% of small cell lung cancer (SCLC) patients do not respond well to initial platinum-based first-line chemotherapy. Knowledge about the clinicopathologic characteristics of these primary drug-resistant populations is limited. This study aimed to explore the clinicopathologic characteristics in SCLC populations insensitive to initial chemotherapy. This study enrolled SCLC patients with insensitivity to initial chemotherapy and analyzed their clinicopathological characteristics. Binary logistic regression analysis was used to determine the independent factors that influence chemosensitivity. The study evaluated 142 cases to determine the clinicopathologic characteristics of SCLC populations with insensitivity to initial chemotherapy. Between the chemotherapy-insensitive group (n = 32) and the chemotherapy-sensitive group (n = 110), no significant differences were observed in sex, age, smoking status, tumor size, lymph-node metastasis, vascular invasion, carcinomatous lymphangitis, mediastinal invasion, superior vena cava syndrome, tumor stage, brain metastases, pleural metastasis, lung metastasis, adrenal metastasis, or the immunohistochemical markers cytokeratin, synaptophysin, chromogranin A, thyroid transcription factor-1, and Ki-67 (all P > .05). However, significant differences in liver metastasis (P = .005), bone metastasis (P < .001), and neural cell adhesion molecule expression (P = .027) were identified. Binary logistic regression analysis revealed that bone metastasis (P = .008) was an independent high-risk factor for insensitivity to initial first-line chemotherapy. Bone metastasis is an independent high-risk factor for insensitivity to initial chemotherapy in SCLC. Enhancing our understanding of SCLC biology and osteoimmuno-oncology could identify new vulnerabilities and better define patient populations that may benefit from tailored clinical treatments to overcome drug resistance.

01 Feb 2025·European Journal of Nutrition

Causal association of serum vitamin D levels with urolithiasis: a bidirectional two-sample Mendelian randomization study

Article

Author: Zhang, He-Zhen ; Zeng, Li-Yuan ; Zhang, Qi-Feng ; Wang, Sheng

BACKGROUNDIn light of inconsistent evidence from previous observational studies regarding the correlation between serum vitamin D levels and urolithiasis, this study aimed to investigate the genome-wide causal association between genetically predicted serum 25(OH)D levels and urolithiasis using the Mendelian randomization (MR) approach.METHODSIn this study, we utilized genome-wide association studies (GWAS) summary statistics from the UK Biobank and SUNLIGHT consortium for serum vitamin D levels, as well as urolithiasis data from FinnGen. We employed bidirectional two-sample MR analysis to evaluate potential causal relationships. The primary MR analysis relied on the inverse variance weighted (IVW) method, supplemented by MR-Egger, weighted median, and weighted mode approaches. Sensitivity analyses were conducted to ensure result robustness, including Cochran's Q test, MR-Egger intercept test, leave-one-out tests, and MR pleiotropy residual sum and outlier (MR-PRESSO) test.RESULTSThe MR analysis indicated no significant causal effects of serum 25(OH)D levels on urolithiasis [IVW method: (kidney and ureteral stones: OR = 1.134;95% CI, 0.953 to 1.350, p = 0.155; lower urinary tract stones: OR = 1.158; 95% CI, 0.806 to 1.666, p = 0.428)]. However, according to the IVW results, genetically predicted kidney and ureteral stones were associated with decreased serum 25(OH)D levels (beta = -0.025; 95% CI, -0.048 to -0.003; p = 0.028), while they did not indicate a causal effect of lower urinary tract stones on serum 25(OH)D levels (beta = -0.002; 95% CI, -0.013 to -0.008; p = 0.662). A sensitivity analysis suggested the robustness of these causal associations.CONCLUSIONSOur MR study did not provide evidence supporting a causal association between serum 25(OH)D levels and urolithiasis among individuals of European descent. However, there might exist a negative causal association between kidney and ureteral stones and serum 25(OH)D levels.

100 Deals associated with Guilin People's Hospital

100 Translational Medicine associated with Guilin People's Hospital

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 11 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Guilin People's Hospital

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 11 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing